Income after Taxes: Earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Ultragenyx Pharmaceutical Inc. (RARE) had Income after Taxes of $-569.18M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$560.23M |
|
$-569.18M |
|
$76.73M |
|
$483.50M |
|
$1.10B |
|
$-535.97M |
|
$-31.61M |
|
$-567.59M |
|
$-567.59M |
|
|
Income after Taxes |
$-569.18M |
$-569.18M |
|
$-569.18M |
|
$-569.18M |
|
$-535.97M |
|
$-513.05M |
|
90.54M |
|
90.54M |
|
$-6.29 |
|
$-6.29 |
|
| Balance Sheet Financials | |
$817.12M |
|
$265.93M |
|
$686.33M |
|
$1.50B |
|
$344.15M |
|
-- |
|
$904.01M |
|
$1.25B |
|
$255.30M |
|
$32.58M |
|
$255.30M |
|
92.48M |
|
| Cash Flow Statement Financials | |
$-414.19M |
|
$-17.77M |
|
$399.24M |
|
$219.40M |
|
$184.16M |
|
$-35.24M |
|
$158.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
86.30% |
|
-95.67% |
|
-95.67% |
|
-91.58% |
|
-101.31% |
|
-101.60% |
|
$-421.68M |
|
-- |
|
-- |
|
-- |
|
0.37 |
|
1.70 |
|
4.60 |
|
79.36 |
|
-222.95% |
|
-1747.19% |
|
-37.86% |
|
-222.95% |
|
$2.76 |
|
$-4.66 |
|
$-4.57 |
|